MEIP Quote, Financials, Valuation and Earnings

iBio has a net margin of -- compared to MEI Pharma's net margin of -4444.57%. MEI Pharma's return on equity of -- beat iBio's return on equity of -148.3%.

MEI Pharma has a consensus price target of --, signalling upside risk potential of 700%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that MEI Pharma has higher upside potential than iBio, analysts believe MEI Pharma is more attractive than iBio.

MEI Pharma has a beta of 0.790, which suggesting that the stock is 21.017% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

MEI Pharma has a quarterly dividend of $1.75 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MEI Pharma pays 65.59% of its earnings as a dividend. iBio pays out -- of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MEI Pharma quarterly revenues are --, which are smaller than iBio quarterly revenues of $175K. MEI Pharma's net income of -$8M is lower than iBio's net income of -$4M. Notably, MEI Pharma's price-to-earnings ratio is 1.16x while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MEI Pharma is 0.16x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to MEI Pharma's net margin of -49.65%. MEI Pharma's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MEI Pharma has a consensus price target of --, signalling upside risk potential of 700%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that MEI Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe MEI Pharma is more attractive than NovaBay Pharmaceuticals.

MEI Pharma has a beta of 0.790, which suggesting that the stock is 21.017% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

MEI Pharma has a quarterly dividend of $1.75 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MEI Pharma pays 65.59% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MEI Pharma quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MEI Pharma's net income of -$8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, MEI Pharma's price-to-earnings ratio is 1.16x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MEI Pharma is 0.16x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to MEI Pharma's net margin of -2357.27%. MEI Pharma's return on equity of -- beat Palatin Technologies's return on equity of --.

MEI Pharma has a consensus price target of --, signalling upside risk potential of 700%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than MEI Pharma, analysts believe Palatin Technologies is more attractive than MEI Pharma.

MEI Pharma has a beta of 0.790, which suggesting that the stock is 21.017% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

MEI Pharma has a quarterly dividend of $1.75 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MEI Pharma pays 65.59% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MEI Pharma quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. MEI Pharma's net income of -$8M is lower than Palatin Technologies's net income of -$7.8M. Notably, MEI Pharma's price-to-earnings ratio is 1.16x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MEI Pharma is 0.16x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -- compared to MEI Pharma's net margin of -63.65%. MEI Pharma's return on equity of -- beat Revance Therapeutics's return on equity of --.

MEI Pharma has a consensus price target of --, signalling upside risk potential of 700%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 147.96%. Given that MEI Pharma has higher upside potential than Revance Therapeutics, analysts believe MEI Pharma is more attractive than Revance Therapeutics.

MEI Pharma has a beta of 0.790, which suggesting that the stock is 21.017% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

MEI Pharma has a quarterly dividend of $1.75 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MEI Pharma pays 65.59% of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MEI Pharma quarterly revenues are --, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. MEI Pharma's net income of -$8M is higher than Revance Therapeutics's net income of -$38.1M. Notably, MEI Pharma's price-to-earnings ratio is 1.16x while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MEI Pharma is 0.16x versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.